Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hanmi Does It Again - RAF Inhibitor Goes To Genentech In $910m Deal

Executive Summary

After a series of blockbuster licensing deals last year, South Korea’s Hanmi has struck another major alliance, this time licensing out a novel oral RAF inhibitor that will strengthen biosimilar-threatened Genentech’s oncology portfolio.

You may also be interested in...



Big Pharma’s Partnering Process: An Insight Into The Nitty-Gritty

Amid ongoing interest in accessing innovative assets, including those from South Korea, big pharma participants at a recent symposium in Seoul shared the ins and outs of the complex partnering process.

2016 Review: Mixed Bag Of Hope, Setbacks For Korean Pharma

For the South Korean pharma industry, 2016 was largely about major global advances for a wide range of biosimilars, accompanied but some setbacks in the area of novel drug development.

Hanmi Toughens Controls As Employees Arrested For Insider Trading

Prosecutors' two-month probe into Hanmi Pharmaceutical has concluded without a big bang after they found the South Korean firm did not intentionally delay the disclosure of a licensee decision to end a cancer drug partnership, but several employees have nevertheless been arrested over improper information leakage.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel